Zhou Zhao, Xue Ma, Yuanmeng Li, Shi-Hui Zhou, Li-E Zang, Fan Feng, Naishi Li
{"title":"Combination Antitumor Activation of Anlotinib with Radiofrequency Ablation in Human Medullary Thyroid Carcinoma.","authors":"Zhou Zhao, Xue Ma, Yuanmeng Li, Shi-Hui Zhou, Li-E Zang, Fan Feng, Naishi Li","doi":"10.2174/0115665240323681241023100958","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Currently, Medullary Thyroid Carcinoma (MTC) is considered a kind of rare neuroendocrine tumor, and molecular-targeted drugs have previously been used for MTC treatment. However, the prognosis of MTC patients is still unsatisfactory. In the present work, we aimed to explore the antitumor activity of the molecularly targeted drug anlotinib in combination with radiofrequency ablation on MTC.</p><p><strong>Methods: </strong>44 MTC clinical specimens were involved. The targets of anlotinib in malignant cells were examined by qPCR. We cultured MTC cells line TT and treated with a series of concentration of TKIs. Then measure the inhibitory rates of TT cell survival. We established a subcutaneous tumorigenic model in nude mice to examine the antitumor effects of anlotinib combined with different RFA conditions.</p><p><strong>Results: </strong>The targets of anlotinib were clearly expressed in MTC tissue specimens, and the expression level of these factors was much higher in MTC clinical specimens than in nontumor tissues. At the same time, anlotinib or Radiofrequency Ablation (RFA) showed clear antitumor activity against the MTC cell line TT (TT cells) and the tumor tissue it formed.</p><p><strong>Conclusion: </strong>These results indicated that the combination of anlotinib with RFA could be a promising therapeutic strategy for MTC treatment.</p>","PeriodicalId":10873,"journal":{"name":"Current molecular medicine","volume":" ","pages":"1167-1180"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current molecular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115665240323681241023100958","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Currently, Medullary Thyroid Carcinoma (MTC) is considered a kind of rare neuroendocrine tumor, and molecular-targeted drugs have previously been used for MTC treatment. However, the prognosis of MTC patients is still unsatisfactory. In the present work, we aimed to explore the antitumor activity of the molecularly targeted drug anlotinib in combination with radiofrequency ablation on MTC.
Methods: 44 MTC clinical specimens were involved. The targets of anlotinib in malignant cells were examined by qPCR. We cultured MTC cells line TT and treated with a series of concentration of TKIs. Then measure the inhibitory rates of TT cell survival. We established a subcutaneous tumorigenic model in nude mice to examine the antitumor effects of anlotinib combined with different RFA conditions.
Results: The targets of anlotinib were clearly expressed in MTC tissue specimens, and the expression level of these factors was much higher in MTC clinical specimens than in nontumor tissues. At the same time, anlotinib or Radiofrequency Ablation (RFA) showed clear antitumor activity against the MTC cell line TT (TT cells) and the tumor tissue it formed.
Conclusion: These results indicated that the combination of anlotinib with RFA could be a promising therapeutic strategy for MTC treatment.
期刊介绍：
Current Molecular Medicine is an interdisciplinary journal focused on providing the readership with current and comprehensive reviews/ mini-reviews, original research articles, short communications/letters and drug clinical trial studies on fundamental molecular mechanisms of disease pathogenesis, the development of molecular-diagnosis and/or novel approaches to rational treatment. The reviews should be of significant interest to basic researchers and clinical investigators in molecular medicine. Periodically the journal invites guest editors to devote an issue on a basic research area that shows promise to advance our understanding of the molecular mechanism(s) of a disease or has potential for clinical applications.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
